Antibody-Drug Conjugate

Ian E. Krop, MD, PhD, associate chief of the division of breast oncology in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, spoke with Healio about recent findings from the DESTINY-Breast03 trial.

In this video, Ian E. Krop, MD, PhD, associate chief of the division of breast oncology in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, discusses results from the TROPION-PanTumor01 study.

In this video, Stan Lipkowitz, MD, PhD, chief of the women's malignancies branch in the National Cancer Institute's Center for Cancer Research, discusses a session on the development of HER2 targeted therapies for breast cancer at AACR-NCI-EORTC.

In an interview with Healio, Pasi A. Jänne, MD, PhD, discussed a study on the use of an antibody-drug conjugate in some patients with non-small cell lung cancer.

Treatment with [vic-]trastuzumab duocarmazine significantly improved PFS compared with physician’s choice of treatment in patients with pretreated locally advanced or metastatic HER2-positive breast cancer, according to phase 3 SYD985.002/TULIP trial data presented at the virtual ESMO Congress.

The FDA granted priority review to tisotumab vedotin for treatment of certain women with cervical cancer, according to the agent’s manufacturer.

The FDA granted regular approval to sacituzumab govitecan for treatment of certain patients with triple-negative breast cancer.

In this video, Debu Tripathy, MD, professor and chair of the department of breast medical oncology at The University of Texas MD Anderson Cancer Center and HemOnc Today Editorial Board member, discussed the exciting potential of antibody drug conjugates.

In this video, Patrick Borgen, MD, chair of the department of surgery at Maimonides Medical Center, discussed the effectiveness of antibody-drug conjugates in the breast cancer setting and the promise of oral taxanes at the 38th Annual Miami Breast Cancer Conference.

Camidanlumab tesirine, a novel pyrrolobenzodiazepine-based antibody-drug conjugate, showed encouraging anti-tumor activity in heavily pretreated patients with relapsed or refractory Hodgkin lymphoma, according to phase 2 data.